ARVN实时信号 | 通过Getagraph.com最大化利润

购买 107684 min ago

@ $49.33

发出时间: 15 Feb 2024 @ 04:32

回报率: -35.41%

上一信号: Feb 14 - 23:03

上一信号: 出售

回报率: 2.08 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:16):

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins...

Stats
今日成交量	192 332
平均成交量	775 327
市值	2.18B
EPS	$0 ( 2024-02-22 )
下一个收益日期	( $-1.480 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.81
ATR14	$0.0510 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Berkowitz Noah	Buy	93 879	Stock Option (right to buy)
2024-03-18	Berkowitz Noah	Buy	63 452	Common Stock
2024-03-18	Berkowitz Noah	Buy	0
2024-02-29	Teel Randy	Sell	0	Common Stock
2024-02-29	Teel Randy	Sell	0	Common Stock

INSIDER POWER
45.52
Last 95 transactions
Buy: 1 590 588 \| Sell: 490 115

音量相关性

長: 0.26 (neutral)

短: -0.39 (neutral)

Signal:(28.005) Neutral

Arvinas Inc 相关性

10 最正相关
XMTR	0.905
PRSO	0.902
TRS	0.899
GMBL	0.898
SELB	0.898
SPTN	0.898
AMNB	0.897
ROIC	0.896
ESSA	0.895
ALIM	0.894

10 最负相关
TVTY	-0.902
WLTW	-0.898
BTAQ	-0.897
SGEN	-0.893
USLM	-0.891
GPACU	-0.887
FRSG	-0.885
NVSA	-0.883
GVCI	-0.883
MLAI	-0.881

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Arvinas Inc 相关性 - 货币/商品

-0.18
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.22
( neutral )

0.55
( weak )

0.37
( neutral )

Arvinas Inc 财务报表

Annual	2023
营收:	$78.50M
毛利润:	$71.80M (91.46 %)
EPS:	$-6.62

FY	2023
营收:	$78.50M
毛利润:	$71.80M (91.46 %)
EPS:	$-6.62

FY	2022
营收:	$131.40M
毛利润:	$123.20M (93.76 %)
EPS:	$-5.11

FY	2021
营收:	$46.00M
毛利润:	$46.00M (100.00 %)
EPS:	$-3.82

Financial Reports:

No articles found.

Arvinas Inc

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

实时更新： Arvinas Inc [ARVN]

Upcoming Earnings Alert